In vitro characterization of jet-milled and in-situ-micronized fluticasone-17-propionate

International Journal of Pharmaceutics

Volumn 258, Issue 1-2, 2003, Pages 65-75

  Steckel, Hartwig ^a   Rasenack, Norbert ^a   Villax, Peter ^b   Müller, Bernd W ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b Hovione SA   (Portugal)

Author keywords

Controlled crystallization; Dry powder inhaler; FlowCaps ; Fluticasone 17 propionate; In situ micronization; Pulmonary drug delivery

Indexed keywords

ACETONE; CELLULOSE; DFS 0227; ETHER; FLUTICASONE 17 PROPIONATE; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTALLIZATION; DRUG DELIVERY SYSTEM; DRUG SOLUTION; DRUG SYNTHESIS; HYDROPHILICITY; MOLECULAR DYNAMICS; PARTICLE SIZE; PHYSICAL CHEMISTRY; POWDER INHALER; PRECIPITATION; PRIORITY JOURNAL; X RAY ANALYSIS;

EID: 0037838336     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(03)00153-4     Document Type: Article

References (32)

1. Briggner L.E., Buckton G., Bystrom K., Darcy P. The use of isothermal microcalorimetry in the study of changes in crystallinity induced during the processing of powders. Int. J. Pharm. 105:1994;125-135.
2. Buckton G. Characterization of small changes in the physical properties of powders of significance for dry powder inhaler formulations. Adv. Drug Del. Rev. 26:1997;17-27.
3. Chang S.A., Gray D.G. The surface tension of aqueous hydroxypropyl cellulose solutions. J. Colloid Interface Sci. 67:1978;255-265.
4. Chew N.Y.K., Chan H.K. Influence of particle size, air flow, and inhaler device on the dispersion of mannitol powders as aerosols. Pharm. Res. 16:1999;1098-1103.
5. Edwards D.A., Hanes J., Caponetti G., Hrkach J., Ben-Jebria A., Eskew M.L., Mintzes J., Deaver D., Lotan N., Langer R. Large porous particles for pulmonary drug delivery. Science. 276:1997;1868-1871.
6. Elamin A.A., Sebhatu T., Ahlneck C. The use of amorphous model substances to study mechanically activated materials in the solid state. Int. J. Pharm. 199:2000;25-36.
7. Feeley J.C., York P., Sumby B.S., Dicks H. Determination of surface properties and flow characteristics of salbutamol sulphate, before and after micronization. Int. J. Pharm. 172:1998;89-96.
8. Ganderton D. The generation of respirable clouds from coarse powder aggregates. J. Biopharm. Sci. 3:1992;101-105.
9. National Heart, Lung and Blood Institute, National Institute of Health - Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention. NHBLI/WHO workshop report, 1995, NIH publication number 95-3659.
10. Kaneniwa N., Ikekawa A. Influence of ball-milling atmosphere on decrease of molecular weight of polyvinylpyrrolidone powders. Chem. Pharm. Bull. 20:1972;1536-1543.
11. Mackin L., Sartnurak S., Thomas I., Moore S. The impact of low levels of amorphous material (<5%) on the blending characteristics of a direct compression formulation. Int. J. Pharm. 231:2002;213-226.
12. Malcolmson R.J., Embleton J.K. Dry powder formulations for pulmonary delivery. Pharm. Sci. Technol. Today. 1:1998;394-398.
13. Moshashaée S., Bisrat M., Forbes R.T., Nyquist H., York P. Supercritical fluid processing of proteins I: lysozyme precipitation from organic solution. Eur. J. Pharm. Sci. 11:2000;239-245.
14. Müller R.H., Peters K., Becker R., Kruss B. Nanosuspensions for the i.v. administration of poorly soluble drugs - stability during sterilization and long-term storage. Proc. Int. Symp. Control Rel. Bioact. Mater. 22:1996;574-575.
15. Niven R. Powders and processing: deagglomerating a dose of patents and publications. Proc. Respir. Drug Del. VIII:2002;257-266.
16. Ogura K., Sobue H. Changes in morphology with milling of the commercial microcrystalline cellulose. J. Appl. Polymer Sci. 14:1970;1390-1393.
17. Parrott, E.L., 1990. Comminution. In: Swarbrick, J., Boylan, J.C. (Eds.), Encyclopedia of Pharmaceutical Technology, vol. 3. Marcel Decker, New York, pp. 101-121.
18. Rasenack N., Müller B.W. Dissolution rate enhancement by in-situ-micronization of poorly water-soluble drugs using a controlled crystallization process. Pharm. Res. 19:2002;1896-1902.
19. Roberts R.J., Rowe R.C., York P. The relationship between indentation hardness of organic solids and their molecular structure. J. Mater. Sci. 29:1994;2289-2296.
20. Sacchetti, M., vanOort, M.M., 1996. Spray-drying and supercritical fluid particle generation techniques. In: Hickey, A.J. (Ed.), Inhalation Aerosols - Physical and Biological Basis for Therapy. Marcel Dekker, New York, pp. 337-384.
21. Schott, H., 1985. Colloidal dispersions. In: Remington's Pharmaceutical Sciences. The Philadelphia College of Pharmacy and Science, Philadelphia, pp. 286-289.
22. Steckel H., Thies J., Müller B.W. Micronizing of steroids for pulmonary delivery by supercritical carbon dioxide. Int. J. Pharm. 152:1997;99-110.
23. Taylor D.A., Jensen M.W., Kanabar V., Engelstätter R., Steinijans V.W., Barnes P.J., O'Connor B.J. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients. Am. J. Respir. Crit. Care Med. 160:1999;237-243.
24. Taylor K.M.G., Pancholi K., Wong D.Y.T. In-vitro evaluation of dry powder inhaler formulations of micronized and milled nedocromil sodium. Pharm. Pharmacol. Commun. 5:1999;255-257.
25. Ticehurst M.D., Basford P.A., Dallman C.I., Lukas T.M., Marshall P.V., Nichols G., Smith D. Characterisation of the influence of micronisation on the crystallinity and physical stability of revatropate hydrobromide. Int. J. Pharm. 193:2000;247-259.
26. Villax, P., 2002. FlowCaps®: inhalation efficiency under low airflow conditions. In: Proceedings of the 11th Annual Conference on Dry Powder Inhalers. Management Forum, London.
27. Waltersson J.O., Lundgren P. The effect of mechanical comminution on drug stability. Acta Pharm. Suec. 22:1985;291-300.
28. Ward G.H., Schultz R.K. Process-induced crystallinity changes in albuterol sulfate and its effect on powder physical stability. Pharm. Res. 12:1995;773-779.
29. Williams R.O., Brown J., Liu J. Influence of micronization method on the performance of a suspension triamcinolone acetonide pressurized metered-dose inhaler formulation. Pharm. Dev. Technol. 4:1999;167-179.
30. Yang T.T., Li S., Wyka B., Kenyon D. Drug delivery performance of the mometasone furoate dry powder inhaler. J. Aerosol Med. 14:2001;487-494.
31. York P. Powdered raw materials: characterizing batch uniformity. Proc. Respir. Drug Del. IV:1994;83-91.
32. Zimon, A.D., 1969. Adhesion of Dust and Powder. Plenum Press, New York.